Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
- PMID: 28202713
- PMCID: PMC5310969
- DOI: 10.1136/bmj.i6583
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
Abstract
Objectives To assess the overall effect of vitamin D supplementation on risk of acute respiratory tract infection, and to identify factors modifying this effect.Design Systematic review and meta-analysis of individual participant data (IPD) from randomised controlled trials.Data sources Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and the International Standard Randomised Controlled Trials Number registry from inception to December 2015.Eligibility criteria for study selection Randomised, double blind, placebo controlled trials of supplementation with vitamin D3 or vitamin D2 of any duration were eligible for inclusion if they had been approved by a research ethics committee and if data on incidence of acute respiratory tract infection were collected prospectively and prespecified as an efficacy outcome.Results 25 eligible randomised controlled trials (total 11 321 participants, aged 0 to 95 years) were identified. IPD were obtained for 10 933 (96.6%) participants. Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants (adjusted odds ratio 0.88, 95% confidence interval 0.81 to 0.96; P for heterogeneity <0.001). In subgroup analysis, protective effects were seen in those receiving daily or weekly vitamin D without additional bolus doses (adjusted odds ratio 0.81, 0.72 to 0.91) but not in those receiving one or more bolus doses (adjusted odds ratio 0.97, 0.86 to 1.10; P for interaction=0.05). Among those receiving daily or weekly vitamin D, protective effects were stronger in those with baseline 25-hydroxyvitamin D levels <25 nmol/L (adjusted odds ratio 0.30, 0.17 to 0.53) than in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (adjusted odds ratio 0.75, 0.60 to 0.95; P for interaction=0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted odds ratio 0.98, 0.80 to 1.20, P=0.83). The body of evidence contributing to these analyses was assessed as being of high quality.Conclusions Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall. Patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit.Systematic review registration PROSPERO CRD42014013953.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at
Figures


Comment in
-
Making uncertainty work.BMJ. 2017 Feb 16;356:j815. doi: 10.1136/bmj.j815. BMJ. 2017. PMID: 28209588 No abstract available.
-
Review: In children and adults, vitamin D3 supplementation reduces risk for acute respiratory tract infection.Ann Intern Med. 2017 May 16;166(10):JC51. doi: 10.7326/ACPJC-2017-166-10-051. Ann Intern Med. 2017. PMID: 28505635 No abstract available.
-
Vitamin D reduces respiratory tract infections frequency.J Pediatr. 2017 Jul;186:209-212. doi: 10.1016/j.jpeds.2017.04.021. J Pediatr. 2017. PMID: 28648275 No abstract available.
-
Weniger akute Atemwegsinfekte durch Vitamin-D-Supplementation?Laryngorhinootologie. 2018 Aug;97(8):524-525. doi: 10.1055/a-0648-6964. Epub 2018 Aug 6. Laryngorhinootologie. 2018. PMID: 30081412 German.
-
PURL: Can vitamin D prevent acute respiratory infections?J Fam Pract. 2019 May;68(4):230-231. J Fam Pract. 2019. PMID: 31226177 Free PMC article.
-
Vitamin D deficiency and the COVID-19 pandemic.J Glob Antimicrob Resist. 2020 Sep;22:133-134. doi: 10.1016/j.jgar.2020.05.006. Epub 2020 May 29. J Glob Antimicrob Resist. 2020. PMID: 32474141 Free PMC article.
-
Facing COVID-19 and Refugee Camps on the U.S. Border.J Emerg Med. 2020 Jul;59(1):143-145. doi: 10.1016/j.jemermed.2020.04.041. J Emerg Med. 2020. PMID: 32900460 Free PMC article. No abstract available.
References
-
- Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009;302:758-66. 10.1001/jama.2009.1163 pmid:19690308. - DOI - PMC - PubMed
-
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71. 10.1016/S0140-6736(14)61682-2 pmid:25530442. - DOI - PMC - PubMed
-
- Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006;134:1129-40. 10.1017/S0950268806007175 pmid:16959053. - DOI - PMC - PubMed
-
- Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol 2013;136:321-9. 10.1016/j.jsbmb.2012.11.017 pmid:23220552. - DOI - PubMed
-
- Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 2008;181:7090-9. 10.4049/jimmunol.181.10.7090 pmid:18981129. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical